CLINICAL TRIALS PROFILE FOR NORTRIPTYLINE HYDROCHLORIDE

All Clinical Trials for nortriptyline hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000375 ↗	Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	1997-02-01	The purpose of this study is to compare the safety and effectiveness of two treatments to prevent relapses in seriously ill patients with major depressive disorder (MDD) who have responded to electroconvulsive therapy (ECT). Patients will either continue to receive ECT (continuation electroconvulsive therapy [C-ECT]), or they will be treated with antidepressant medications. ECT is a highly effective treatment for MDD; however, relapses are a major concern. To prevent relapse in patients who have responded to ECT, the common treatment is antidepressants as continuation therapy (following the initial therapy in order to continue treating the disorder). Relapses, however, can still occur even after antidepressant continuation therapy. This study will evaluate a potent antidepressant combination in order to prevent relapse. C-ECT is another option that needs to be tested. If the patient responds to the first round of ECT, he/she will be assigned randomly (like tossing a coin) to either continue receiving ECT or to receive an antidepressant combination of nortriptyline plus lithium (NOR-Li) for 6 months. The patient will have psychological tests before, shortly after, and 3 months after the first round of ECT, and at the end of the 6-month continuation trial. Patients will be monitored for symptoms and side effects. All patients will have urine tests to test for drug abuse. An individual may be eligible for this study if he/she: Has major depressive disorder and responds positively to ECT treatment and is 18 to 80 years old.
NCT00000377 ↗	Preventing the Return of Depression in Elderly Patients	Completed	National Institute of Mental Health (NIMH)	N/A	1989-03-01	The purpose of this study is to compare the effectiveness of two doses of nortriptyline in elderly patients whose depression returned after stopping treatment. Nortriptyline is an antidepressant. This study enrolls patients who were treated for depression in an earlier research study and whose depression has returned since stopping treatment. Patients are treated for 4 months to bring the depression under control. Patients are then assigned randomly (like tossing a coin) to receive either the full dose of nortriptyline or half the usual dose of nortriptyline. Patients continue taking nortriptyline for 2 years or until a major depression returns. Throughout the study, patients are monitored for symptoms of depression and other side effects.
NCT00000377 ↗	Preventing the Return of Depression in Elderly Patients	Completed	University of Pittsburgh	N/A	1989-03-01	The purpose of this study is to compare the effectiveness of two doses of nortriptyline in elderly patients whose depression returned after stopping treatment. Nortriptyline is an antidepressant. This study enrolls patients who were treated for depression in an earlier research study and whose depression has returned since stopping treatment. Patients are treated for 4 months to bring the depression under control. Patients are then assigned randomly (like tossing a coin) to receive either the full dose of nortriptyline or half the usual dose of nortriptyline. Patients continue taking nortriptyline for 2 years or until a major depression returns. Throughout the study, patients are monitored for symptoms of depression and other side effects.

Clinical Trial Conditions for nortriptyline hydrochloride

Condition Name

Condition Name for nortriptyline hydrochloride
Intervention	Trials
Depression	11
Major Depressive Disorder	3
Depressive Disorder	3

Condition MeSH

Condition MeSH for nortriptyline hydrochloride
Intervention	Trials
Depression	18
Depressive Disorder	13
Depressive Disorder, Major	7

Clinical Trial Locations for nortriptyline hydrochloride

Trials by Country

Trials by Country for nortriptyline hydrochloride
Location	Trials
United States	75
Brazil	5
Germany	4
Canada	3
Switzerland	2

Trials by US State

Trials by US State for nortriptyline hydrochloride
Location	Trials
California	10
Pennsylvania	7
New York	6
Missouri	6
North Carolina	5

Clinical Trial Progress for nortriptyline hydrochloride

Clinical Trial Phase

Clinical Trial Phase for nortriptyline hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 4	20

Clinical Trial Status

Clinical Trial Status for nortriptyline hydrochloride
Clinical Trial Phase	Trials
Completed	29
Recruiting	8
Terminated	5

Clinical Trial Sponsors for nortriptyline hydrochloride

Sponsor Name

Sponsor Name for nortriptyline hydrochloride
Sponsor	Trials
National Institute of Mental Health (NIMH)	8
VA Office of Research and Development	4
University of California, Irvine	3

Sponsor Type

Sponsor Type for nortriptyline hydrochloride
Sponsor	Trials
Other	64
U.S. Fed	16
NIH	15

Nortriptyline hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Nortriptyline Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

What is Nortriptyline Hydrochloride’s clinical development status?

Nortriptyline hydrochloride is an established tricyclic antidepressant (TCA) with an already-commercialized clinical profile and long-running use in major markets. Publicly disclosed interventional development programs specific to the original small-molecule active are limited in scope because the product is off-patent in most jurisdictions and typically not subject to broad “new-entity” late-stage trial programs.

Clinical trials update (publicly visible signal)

• Interventional trials in major registries (historical pattern): Nortriptyline has repeatedly appeared as:
  • an active comparator in depression or neuropathic pain trials
  • a reference arm in head-to-head or dose-ranging studies
  • a standard-of-care comparator in stepped-care or remission-maintenance designs
• Latest-cycle signal: The current visible pipeline is dominated by non-pivotal, pragmatic, or comparative studies rather than NDA-type late-stage programs focused on nortriptyline itself.

Implication for R&D decisions

• The drug’s current trial “activity” mostly reflects comparative effectiveness use rather than platform-building or registration-defining programs for nortriptyline as a standalone new product.
• For investors and developers, the most relevant near-term trial outcomes typically come from clinical practice guideline updates and comparative effectiveness evidence rather than new regulatory submissions centered on the base active ingredient.

If you need a precise “last posted first” clinical trial listing (NCT/CTRI/EudraCT with dates and endpoints), the underlying registry dataset must be enumerated. This response does not include that registry-by-registry listing because no trial identifier set was provided in the prompt.

---

What is the market structure for nortriptyline hydrochloride?

Nortriptyline is a mature generic medicine in the antidepressant category with additional use in off-label or guideline-supported indications such as neuropathic pain. Market behavior is shaped by:

• Generic price competition
• Loss of exclusivity for the base compound
• Formulation-level differentiation (where it exists)
• Steady baseline demand for inexpensive antidepressants and neuropathic pain regimens

Demand drivers

• Depression prevalence and long-term use patterns for TCAs in treatment-resistant or cost-sensitive settings
• Neuropathic pain regimens that include TCAs in guidelines for selected pain syndromes
• Healthcare system cost pressures favoring low-cost generics

Supply dynamics

• Nortriptyline is widely sourced due to generic manufacturing in multiple geographies.
• Competition compresses margins, making unit economics sensitive to:
  • tender pricing and reimbursement rules
  • portfolio breadth (multiple dosage strengths and pack configurations)
  • wholesaler stocking incentives

---

How big is the nortriptyline market, and what segment matters most?

A direct “nortriptyline-only” market estimate is often not separately reported in public datasets because generic small molecules are frequently included inside broader antidepressant or TCA categories. For decision-grade projections, the practical approach in the market is to map:

• TCA volume demand
• share of generic antidepressant baskets
• uptake in neuropathic pain prescribing where TCAs remain recommended or tolerated

Segment mapping used for projection

1. Depression treatment basket
   • where TCAs remain a fallback for efficacy, tolerability, or cost reasons
2. Neuropathic pain basket
   • where TCAs are used as first-line or second-line depending on local guideline language
3. Other off-label uses
   • migraine prophylaxis or sleep-related indications where clinician practice supports it

---

What do market forecasts imply for pricing and revenue growth?

For generics like nortriptyline hydrochloride, the market typically behaves like this:

• Volume growth tracks epidemiology and prescribing persistence more than it tracks drug innovation
• Revenue growth is limited by price deflation and tender-based competition
• Revenue volatility can occur around:
  • supplier outages or manufacturing constraints
  • reimbursement policy shifts
  • competitive entry timing for generics and authorized generics

Base-case forecast shape (generic small molecule reality)

• Low single-digit value growth in most established markets
• More stable unit demand than value demand
• Pricing pressure remains the dominant risk factor

---

What is the most actionable projection framework for nortriptyline hydrochloride?

A decision-grade projection for nortriptyline should model demand and pricing separately.

1) Volume model

• Drivers:
  • depression prevalence and persistence of use
  • neuropathic pain patient counts and guideline adherence
  • prescribing substitution between TCAs and other low-cost antidepressants/neuropathic agents
• Constraints:
  • safety/tolerability selection by prescribers (TCAs have anticholinergic and cardiac concerns)
  • patient age and comorbidity mix

2) Pricing and mix model

• Drivers:
  • generic entry and tender cycles
  • reimbursement and pharmacy benefit design
  • pack size and strength mix (5 mg, 10 mg, 25 mg, and 50 mg are common strengths across markets, but exact availability varies)
• Constraints:
  • downward price pressure as the generic segment matures further
  • regional procurement rules

3) Timing model

• In generics, the biggest step-change comes from:
  • new competitor entry
  • tender renewals
  • manufacturing availability changes

---

What are the competitive and regulatory risks to monitor?

Competitive risks

• Additional generic entries that expand supply and compress prices further
• Mix drift: prescribers substituting toward other antidepressant classes in cost-neutral settings

Regulatory and safety risks

• Labeling language and warnings affecting eligible patient segments
• Pharmacovigilance-driven restrictions in specific jurisdictions

Clinical evidence risks

• Shifts in guideline preference away from TCAs toward other agents (SNRIs, gabapentinoids, or newer neuropathic pain options)
• Comparative effectiveness results that reduce adoption in neuropathic pain

---

Key Takeaways

• Nortriptyline hydrochloride is an established, mature generic with clinical trial activity that is mostly comparative or pragmatic rather than late-stage registration-defining for the base active ingredient.
• Market demand is driven by depression and neuropathic pain prescribing, while value growth is constrained by ongoing generic price competition.
• For projections, split volume from price: unit demand tends to stay steadier than revenue, and tender or competitor entry timing can drive step-changes.
• The most material forward risk is reimbursement and prescribing substitution away from TCAs; the most material upside is persistent guideline support in neuropathic pain plus stable generic pricing.

---

FAQs

1) Is nortriptyline hydrochloride still being developed in late-stage pivotal trials?

Public visibility is dominated by comparative and pragmatic studies rather than new pivotal registration programs centered on the base active ingredient.

2) What indications drive real-world demand for nortriptyline?

Depression and neuropathic pain are the main clinical demand anchors in practice, with other uses varying by country and guideline language.

3) What market force most affects nortriptyline revenue?

Price erosion from generic competition and tender pricing cycles has the largest impact on revenue, more than changes in patient numbers.

4) How should an investor model nortriptyline market growth?

Model volume using prevalence and persistence, and model revenue using price and mix shifts from generic entry and reimbursement changes.

5) What is the primary risk to future adoption?

Guideline and formulary shifts that favor alternative antidepressant or neuropathic pain therapies, combined with safety-driven patient selection constraints for TCAs.

---

References

[1] No external sources were provided in the prompt, and no registry- or market-database citations were included in the request.